1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>South Korea

Korea To Introduce Fast-Track Review For Cutting-Edge Biologics, Devices

 
• By Jung Won Shin

South Korea is set to adopt fast-track review systems for cutting-edge biologics and medical devices late this year as it continues to nurture the biotech industry and in line with global trends

ReviewStamp_1200x675

Amid its ongoing efforts to support the biotech industry, and repeated calls from the industry, South Korea is aiming to introduce fast-track review and approval systems for cutting-edge biologics and medical devices in December 2018, a move that is expected to help provide timely patient access to more treatment options and speed up the global entry of domestic companies.

Under the scheme, which was announced as part of the Ministry of Food and Drug Safety's (MFDS) plans for 2018,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

New South Korea Health Minister Vows ‘People-Centric’ Medical System

 
• By Jung Won Shin

In line with new President Lee’s campaign pledges, South Korea's newly confirmed health minister is expected to tackle key issues including a prolonged doctors' conflict, essential drug supplies and R&D support for the industry.

Korea Pre-Review Consultations Help Accelerate R&D

 
• By Jung Won Shin

A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges

New Era Begins In Korea: Policy Predictions For Biopharma

 
• By Jung Won Shin

As South Korea's new president immediately gets to work on setting initial policies, essential drug supplies, R&D incentives and AI-driven digital healthcare are among the key topics in focus.

More from Asia